Wound cure co MacroCure raises $13m

Viola Equity Partners invested $10 million, and current investors Pontifax and Docor invested $3 million.

Chronic wound treatment developer MacroCure Ltd. has raised $13 million in a financing round led by Viola Private Equity, which invested $10 million in. Current investors Docor International Management Ltd. and Pontifax Fund also invested $3 million. The financing round brings the total amount invested in MacroCure to $26 million since it was founded in 2008.

MacroCure has developer CureXcell, a cell-based therapy for chronic wounds, which uses activated white blood cells obtained from healthy donors aged18-40. The product is sold in Israel. The company is planning an international Phase III clinical trial of the product on skin ulcers in the legs of diabetics, in order to enter foreign markets.

Viola Private Equity partner Jonathan Kolber said, "MacroCure is a fascinating company with a breakthrough product platform and strong and experienced management team."

Published by Globes [online], Israel business news - www.globes-online.com - on April 27, 2011

© Copyright of Globes Publisher Itonut (1983) Ltd. 2011

View comments in rows
Update by email about comments talkback
Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018